Exendin-4 Improves Reversal of Diabetes in NOD Mice Treated with Anti-CD3 Monoclonal Antibody by Enhancing Recovery of β-Cells
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Immune modulators can arrest loss of insulin secretion in type 1 diabetes mellitus (T1DM), but they have not caused permanent disease remission or restored normal insulin secretion. We tested whether exendin-4, a glucagon-like peptide-1 receptor agonist, would enhance remission of T1DM in NOD mice treated with anti-CD3 monoclonal antibody (mAb) and studied the effects of exendin-4 treatment on cellular and metabolic responses of β-cells. Diabetic NOD mice treated with anti-CD3 mAb and exendin-4 had a higher rate of remission (44%) than mice treated with anti-CD3 mAb alone (37%) or exendin-4 (0%) or insulin or IgG alone (0%) (P < 0.01). The effect of exendin-4 on reversal of diabetes after anti-CD3 mAb was greatest in mice with a glucose level of less than 350 mg/dl at diagnosis (63 vs. 39%, P < 0.05). Exendin-4 did not affect β-cell area, replication, or apoptosis or reduce the frequency of diabetogenic or regulatory T cells or modulate the antigenicity of islet cells. Reversal of T1DM with anti-CD3 mAb was associated with recovery of insulin in glucose transporter-2+/insulin− islet cells that were identified at diagnosis. Glucose tolerance and insulin responses improved in mice treated with combination therapy, and exendin-4 increased insulin content and insulin release from β-cells. We conclude that treatment with glucagon-like peptide-1 receptor agonist enhances remission of T1DM in NOD mice treated with anti-CD3 mAb by enhancing the recovery of the residual islets. This combinatorial approach may be useful in treatment of patients with new-onset T1DM.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies to date that have reported an increase in β-cell mass with glucagon-like peptide 1 (GLP-1)-1 based therapies were undertaken in young rodents (17–21).”
From Age-Dependent Decline in β-Cell Proliferation Restricts the Capacity of β-Cell Regeneration in Mice (2009) · cites this paper as [20]
Citations
Cites
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus
Herold, K. C., Hagopian, W., Auger, J. A., Poumian-Ruiz, E., Taylor, L., Donaldson, D., Gitelman, S. E., Harlan, D. M., Xu, D., Zivin, R. A., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012864 · Cited by 1,222
Self-citationXu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes
Keymeulen, B., Vandemeulebroucke, E., Ziegler, A. G., Mathieu, C., Kaufman, L., Hale, G., Gorus, F., Goldman, M., Walter, M., Candon, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043980 · Cited by 1,099 · cited 2×
“In the European study, the clinical response to drug treatment was most apparent in those subjects in whom the magnitude of the Cpeptide response to a glucose clamp at diagnosis was in the upper half of C-peptide responses of all subjects at diagnosis (3).”
BackgroundAnti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice.
Chatenoud, L., Thervet, E., Primo, J., & Bach, J. F. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.1.123 · Cited by 664 · cited 2×
“(32) and recently reported by our group (18, 31).”
BackgroundFarilla, L., Bulotta, A., Hirshberg, B., Li Calzi, S., Khoury, N., Noushmehr, H., Bertolotto, C., Di Mario, U., Harlan, D. M., & Perfetti, R. (2003) · Endocrinology · doi:10.1210/en.2003-0323 · Cited by 664
Herold, K. C., Gitelman, S. E., Masharani, U., Hagopian, W., Bisikirska, B., Donaldson, D., Rother, K., Diamond, B., Harlan, D. M., & Bluestone, J. A. (2005) · Diabetes · doi:10.2337/diabetes.54.6.1763 · Cited by 634
Self-citationGlucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis
Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P. A., & Drucker, D. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209423200 · Cited by 589
Belghith, M., Bluestone, J. A., Barriot, S., Mégret, J., Bach, J.-F., & Chatenoud, L. (2003) · Nature Medicine · doi:10.1038/nm924 · Cited by 586
Self-citationStoffers, D. A., Kieffer, T. J., Hussain, M. A., Drucker, D. J., Bonner-Weir, S., Habener, J. F., & Egan, J. M. (2000) · Diabetes · doi:10.2337/diabetes.49.5.741 · Cited by 576 · cited 2×
“075 g ip for 10 d, beginning at the onset of hyperglycemia (9, 10, 19).”
BackgroundKolterman, O. G., Buse, J. B., Fineman, M. S., Gaines, E., Heintz, S., Bicsak, T. A., Taylor, K., Kim, D., Aisporna, M., Wang, Y., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021545 · Cited by 552
Young, A. A., Gedulin, B. R., Bhavsar, S., Bodkin, N., Jodka, C., Hansen, B., & Denaro, M. (1999) · Diabetes · doi:10.2337/diabetes.48.5.1026 · Cited by 440 · cited 1×
“When given over weeks, exendin-4 has been shown to increase insulin sensitivity (33).”
BackgroundCD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice
Chatenoud, L., Primo, J., & Bach, J. F. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.6.2947 · Cited by 417 · cited 3×
“075 g ip for 10 d, beginning at the onset of hyperglycemia (9, 10, 19).”
BackgroundResultLieberman, S. M., Evans, A. M., Han, B., Takaki, T., Vinnitskaya, Y., Caldwell, J. A., Serreze, D. V., Shabanowitz, J., Hunt, D. F., Nathenson, S. G., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932778100 · Cited by 388
Progression of autoimmune diabetes driven by avidity maturation of a T-cell population
Amrani, A., Verdaguer, J., Serra, P., Tafuro, S., Tan, R., & Santamaria, P. (2000) · Nature · doi:10.1038/35021081 · Cited by 332
Factors Associated with Early Remission of Type I Diabetes in Children Treated with Cyclosporine
Bougneres, P. F., Carel, J. C., Castano, L., Boitard, C., Gardin, J. P., Landais, P., Hors, J., Mihatsch, M. J., Paillard, M., Chaussain, J. L., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198803173181103 · Cited by 330 · cited 1×
“This is reminiscent of the experience with cyclosporine A where the C-peptide level at entry was a predictor of clinical response to treatment (4).”
ResultBresson, D. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27191 · Cited by 293 · cited 1×
“(32) and recently reported by our group (18, 31).”
BackgroundNeonatal Exendin-4 Prevents the Development of Diabetes in the Intrauterine Growth Retarded Rat
Stoffers, D. A., Desai, B. M., DeLeon, D. D., & Simmons, R. A. (2003) · Diabetes · doi:10.2337/diabetes.52.3.734 · Cited by 261
Trudeau, J. D., Kelly-Smith, C., Verchere, C. B., Elliott, J. F., Dutz, J. P., Finegood, D. T., Santamaría, P., & Tan, R. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16409 · Cited by 232 · cited 4×
“Enumeration of diabetogenic CD8 T cells.”
MethodSreenan, S., Pick, A. J., Levisetti, M., Baldwin, A. C., Pugh, W., & Polonsky, K. S. (1999) · Diabetes · doi:10.2337/diabetes.48.5.989 · Cited by 193
Role of Endogenous Glucagon-Like Peptide-1 in Islet Regeneration After Partial Pancreatectomy
De León, D. D., Deng, S., Madani, R., Ahima, R. S., Drucker, D. J., & Stoffers, D. A. (2003) · Diabetes · doi:10.2337/diabetes.52.2.365 · Cited by 172 · cited 2×
“It is possible that with longer exposure to exendin-4, there might be improved rates of -cell replication, increased -cell area, or reduced -cell apoptosis, as has been suggested by previous studies (7, 12), but this is not suggested by our data in mice followed for 70 d after diabetes onset (Fig.”
BackgroundResultCure of Overt Diabetes in NOD Mice by Transient Treatment With Anti-Lymphocyte Serum and Exendin-4
Ogawa, N., List, J. F., Habener, J. F., & Maki, T. (2004) · Diabetes · doi:10.2337/diabetes.53.7.1700 · Cited by 156 · cited 1×
“(17) in which exendin-4 was used with ALS for treatment of NOD mice with new-onset diabetes but clarify the mechanism to account for synergistic effect of exendin-4 with immune modulators.”
BackgroundEffects of Autoimmunity and Immune Therapy on β-Cell Turnover in Type 1 Diabetes
Sherry, N. A., Kushner, J. A., Glandt, M., Kitamura, T., Brillantes, A.-M. B., & Herold, K. C. (2006) · Diabetes · doi:10.2337/db05-1034 · Cited by 153
Self-citationGlucagon-Like Peptide I Reduces Postprandial Glycemic Excursions in IDDM
Dupre, J., Behme, M. T., Hramiak, I. M., McFarlane, P., Williamson, M. P., Zabel, P., & McDonald, T. J. (1995) · Diabetes · doi:10.2337/diab.44.6.626 · Cited by 151
Prevalent CD8 + T cell response against one peptide/MHC complex in autoimmune diabetes
Anderson, B., Park, B.-J., Verdaguer, J., Amrani, A., & Santamaría, P. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.16.9311 · Cited by 143
Function, Mass, and Replication of Porcine and Rat Islets Transplanted into Diabetic Nude Mice
Davalli, A. M., Ogawa, Y., Scaglia, L., Wu, Y.-J., Hollister, J., Bonner-Weir, S., & Weir, G. C. (1995) · Diabetes · doi:10.2337/diab.44.1.104 · Cited by 134 · cited 1×
“For insulin content analysis, the islet extracts were prepared using an acid/ethanol method with some modifications (24).”
MethodGreenbaum, C. J., Prigeon, R. L., & D’Alessio, D. A. (2002) · Diabetes · doi:10.2337/diabetes.51.4.951 · Cited by 119
Noninvasive imaging of pancreatic inflammation and its reversal in type 1 diabetes
Turvey, S. E. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25048 · Cited by 94 · cited 1×
“(32) and recently reported by our group (18, 31).”
BackgroundGlucagon-like peptide 1 improved glycemic control in type 1 diabetes
Behme, M. T., Dupré, J., & McDonald, T. J. (2003) · BMC Endocrine Disorders · doi:10.1186/1472-6823-3-3 · Cited by 88
Glycaemic effects of incretins in Type 1 diabetes mellitus
Dupre, J. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.06.003 · Cited by 72
Baggio, L., Adatia, F., Bock, T., Brubaker, P. L., & Drucker, D. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005119200 · Cited by 40
Tomita, T. (1999) · Endocrine Pathology · doi:10.1007/bf02738882 · Cited by 24 · cited 1×
“To improve the detection of -cells before and after treatment, additional immunohistochemical staining was performed involving detection of insulin and glucose transporter-2 (GLUT-2) as described (21).”
MethodBaggio, L. L., Holland, D., Wither, J., & Drucker, D. J. (2006) · Diabetes · doi:10.2337/db05-1502 · Cited by 21 · cited 1×
“We considered whether exendin-4 could modify the islets themselves, thereby affecting their antigenicity, or in some way affect the autoimmune response as has been recently suggested (26).”
BackgroundA New Culture Method for Human Pancreatic Islets Using a Biopore Membrane Insert
Hober, C., Benhamou, P., Watt, P. C., Watanabe, Y., Nomura, Y., Stein, E., Brunicardi, F. C., & Mullen, Y. (1997) · Pancreas · doi:10.1097/00006676-199703000-00014 · Cited by 13 · cited 1×
“Twenty islets were placed on a culture plate insert (Millicell-CM; Millipore, Billerica, MA) and kept in culture medium RPMI 1640 supplemented with 10% fetal bovine serum, 10 mm nicotinamide, l-glutamine, and antibiotics at 37 C and 5% CO2 (23).”
Method
Cited by
Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice
Hu, C.-Y., Rodriguez-Pinto, D., Du, W., Ahuja, A., Henegariu, O., Wong, F. S., Shlomchik, M. J., & Wen, L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32405 · Cited by 426
Age-Dependent Decline in β-Cell Proliferation Restricts the Capacity of β-Cell Regeneration in Mice
Tschen, S.-I., Dhawan, S., Gurlo, T., & Bhushan, A. (2009) · Diabetes · doi:10.2337/db08-1651 · Cited by 331
Keymeulen, B., Walter, M., Mathieu, C., Kaufman, L., Gorus, F., Hilbrands, R., Vandemeulebroucke, E., Van de Velde, U., Crenier, L., De Block, C., et al. (2010) · Diabetologia · doi:10.1007/s00125-009-1644-9 · Cited by 317
“Since the beta cell mass is already markedly reduced at clinical onset of type 1 diabetes [18, 19], it is likely that any immune-modulating intervention will have to be associated with, or followed by, a beta cell replacement therapy, as recently tested in rodents [20]; a combination with other methods for tolerance-i…”
Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells
Lee, Y.-S., & Jun, H.-S. (2014) · Metabolism · doi:10.1016/j.metabol.2013.09.010 · Cited by 315
“[78] Sherry NA, Chen W, Kushner JA, et al.”
BackgroundType 1 diabetes as a relapsing–remitting disease?
von Herrath, M., Sanda, S., & Herold, K. (2007) · Nature Reviews Immunology · doi:10.1038/nri2192 · Cited by 270
Self-citation
Metadata
- Authors
- Sherry, N. A., Chen, W., Kushner, J. A., Glandt, M., Tang, Q., Tsai, S., Santamaria, P., Bluestone, J. A., Brillantes, A.-M. B., & Herold, K. C.
- Affiliations
- Columbia University Irving Medical Center (US)
- Yale University (US)
- Children's Hospital of Philadelphia (US)
- University of California, San Francisco (US)
- University of Calgary (CA)
- Julia McFarlane Diabetes Research Centre and Department of Microbiology and Infectious Diseases (S.T., P.S.), University of Calgary, Calgary, Alberta, Canada T2N 1N4
- Corresponding author
- Herold, Kevan C.
- ORCID
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2007-11-01
- Volume
- 148
- Issue
- 11
- Pages
- 5136-5144
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W1983796537
- Cited by
- 169
- References
- 34
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 4 · 2022: 4 · 2021: 5 · 2020: 6 · 2019: 7 · 2018: 4 · 2017: 5 · 2016: 9 · 2015: 7 · 2014: 13 · 2013: 19 · 2012: 16
- FWCI
- 10.39
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pediatric Endocrine Society
- Alberta Heritage Foundation for Medical Research
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases (AI98-010)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK 57846, DK068678, K08DK064101, R01DK068678, P30DK063608, R01DK057846)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- exendin-4, GLP-1 receptor agonists, type 1 diabetes, diabetes remission, anti-CD3 monoclonal antibody, beta-cell recovery, NOD mice, insulin secretion, GLUT2, immunomodulation, combination therapy
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Animals, Antibodies, Monoclonal, Cells, Cultured, Combined Modality Therapy, Diabetes Mellitus, Type 1, Female, Immunotherapy, Peptides, Remission Induction, Venoms, Mice, SCID, Mice, Inbred NOD, CD3 Complex, Receptors, Glucagon, Insulin-Secreting Cells, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.